JAK inhibitors for the treatment of vitiligo

作者：Inoue S, Suzuki T, Sano S, Katayama I · 发表于：Journal of dermatological science · 年份：2024 · DOI：10.1016/j.jdermsci.2023.12.008 · 研究领域：IFN-γ、IL-15、Janus kinase、Ritlecitinib、Ruxolitinib、Vitiligo

Vitiligo is an autoimmune disease involving melanocyte-targeting T cells initiated by environmental and genetic factors. Steroids and tacrolimus have been used as topical treatments. Recently, novel topical agents targeting Janus kinase (JAK), a family of tyrosine kinases that regulates cytokine signaling, have emerged. Ruxolitinib is the first approved in vitiligo therapy. Furthermore, ritlecitinib is currently under clinical trials for oral treatment of active vitiligo. In this review, we discuss the possibility of topical JAK inhibitors as promising options for the treatment of vitiligo with regard to their mechanism of action, efficacy and safety.